← Back to Search


ANAVEX2-73 oral liquid for Rett Syndrome (EXCELLENCE Trial)

Phase 2 & 3
Waitlist Available
Research Sponsored by Anavex Life Sciences Corp.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights


This trial is studying a new drug to treat Rett Syndrome. The drug is being tested for safety, tolerability and efficacy in patients 5-17 years old. Multiple clinical and exploratory measures will be used to assess the drug's effectiveness.

Eligible Conditions
  • Rett Syndrome


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidents of Adverse Events
Secondary outcome measures
Anxiety, Depression, and Mood Scale (ADAMS)
Child Health Questionnaire-Parent Form 50 (CHQ-PF50)
+6 more
Other outcome measures
GABA Plasma Concentration
Genetic variant SIGMAR1, COMT
Glutamate Plasma Concentration
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ANAVEX2-73 ActiveExperimental Treatment1 Intervention
ANAVEX2-73 liquid oral solution
Group II: ANAVEX2-73 PlaceboPlacebo Group1 Intervention
Placebo liquid oral solution
First Studied
Drug Approval Stage
How many patients have taken this drug
ANAVEX2-73 oral liquid
Completed Phase 3

Find a Location

Who is running the clinical trial?

Anavex Life Sciences Corp.Lead Sponsor
12 Previous Clinical Trials
1,610 Total Patients Enrolled
2 Trials studying Rett Syndrome
64 Patients Enrolled for Rett Syndrome
Anavex Australia Pty Ltd.Industry Sponsor
4 Previous Clinical Trials
1,127 Total Patients Enrolled
Anavex Germany GmbHIndustry Sponsor
4 Previous Clinical Trials
1,223 Total Patients Enrolled
~18 spots leftby Jul 2025